Five Prime Targets $200M In Follow-On Offering
Clinical stage biotech firm Five Prime Therapeutics Inc. said it may raise up $200 million with future stock offerings, filing a shelf registration with the U.S. Securities and Exchange Commission on...To view the full article, register now.
Already a subscriber? Click here to view full article